Avisi Technologies Reports Positive 12-Month Results for VisiPlate Aqueous Shunt at AAO 2025

Avisi Technologies has shared promising 12-month clinical results from its VITA trial evaluating the VisiPlate Aqueous Shunt, a next-generation device designed to lower intraocular pressure (IOP) in patients with open-angle glaucoma. The findings were presented at the 2025 American Academy of Ophthalmology (AAO) Annual Meeting by Dr. Jonathan Myers, Chief of the Glaucoma Service at Wills Eye Hospital, Thomas Jefferson University, Philadelphia.

VITA Trial Overview: Design and Patient Profile

The VITA Trial is a prospective pilot study aimed at assessing the safety and efficacy of the VisiPlate Aqueous Shunt. Conducted across three centers in South Africa by three different implanting surgeons, the study enrolled 15 patients, all of whom were diagnosed with open-angle glaucoma and had no prior history of filtration surgery.

The VisiPlate was implanted unilaterally using an ab externo standalone approach.

Key 12-Month Clinical Outcomes

At baseline, patients in the study had the following characteristics:

       • Mean diurnal IOP: 24.1 ± 6.2 mm Hg

       • Glaucoma medications: 2.0 ± 1.5

       • Visual field mean deviation: –11.7 ± 8.6 dB

After 12 months, results demonstrated substantial improvements:

       • Mean diurnal IOP reduced to 13.1 ± 2.6 mm Hg (a 42.6% decrease)

       • Medication burden dropped to 1.3 ± 1.5

       • 46.7% of patients discontinued all glaucoma medications

Importantly, no serious adverse events were reported, and no patients experienced persistent vision loss, supporting the safety profile of the device.

In addition to the VITA study, the VisiPlate Aqueous Shunt is currently being evaluated in the SAPPHIRE trial in the United States, furthering its clinical development pathway.